The type and nature of refractive surgery procedures has greatly increased over the past few decades, allowing for almost all patient populations to be treated to extremely high satisfaction. Conventional photorefractive keratectomy involves the removal of the corneal epithelium through mechanical debridement or dilute alcohol instillation. An improvement to this method utilises laser epithelial removal in a single-step process termed transepithelial photorefractive keratectomy (transPRK). We explore the history of transPRK from its early adoption as a two-step process, identify different transPRK platforms from major manufacturers, and describe the role of transPRK in the refractive surgery armamentarium. This is a narrative review of the literature. This review finds that TransPRK is a safe and effective procedure that works across a variety of patient populations. Though often not seen as a primary treatment option when compared to other corneal-based procedures that offer a faster and more comfortable recovery, there are many scenarios in which these procedures are not possible. These include, but are not limited to, cases of corneal instability, previous refractive surgery, or transplant where higher-order aberrations can impair vision in a manner not amenable to spectacle or contact lens correction. We discuss refinements to the procedure that would help improve outcomes, including optimising patient discomfort after surgery as well as reducing corneal haze and refractive regression.

Objective: To evaluate the clinical and surgical outcomes of femtosecond laser-assisted cataract surgery (FLACS) in hard cataract of Egyptian population. Setting: ICare Center, Alexandria, Egypt. Design: Retrospective observational. Methods: The study included 50 FLACS cases of 40 patients who had cataract; NO4 NC4 or more according to Lens Opacities Classification System III (LOCS III), performed between October 2018 and May 2019. The cases underwent anterior capsulotomy, lens fragmentation, and corneal incisions with the femtosecond laser. Arcuate keratotomy was performed in selected cases. Phacoemulsification and implantation of an intraocular lens are then performed. Results: Patients mean age was 63.06 ± 7.75 yr, mean femtosecond laser energy was 12.92 ± 0.72 mJ, mean docking time was 3.00 ± 0.83 min and overall mean laser treatment time was 92.00 ± 25.01 sec. Mean laser treatment time was lower in cases that did not get astigmatic keratectomy (87.7 ± 18.97 vs 89.47 ± 13.43 sec; p < 0.73). Attempted refraction was − 0.09 ± 0.52 D and achieved 12 months postoperative manifest sphere equivalent refraction (SER) was − 0.19 ± 1.11 D (r = 0.8 and P˂0.001). Mean error (ME) was − 0.2 ± 1.11 (range: − 2.5– 1.5) while mean absolute error (MAE) was 0.97 ± 0.57 (range: 0– 2.5). Eighty percent and 92% of cases had 1 month postoperative SER within 1.0 D and 1.5 D, respectively. One eye (2%) had incomplete capsulotomy, 7 eyes (14%) had incomplete corneal incision and lens fragmentation was complete in all cases except 1 eye (2%). Thirty-four eyes (68%) showed postdocking conjunctival ecchymosis and 35 eyes (70%) had intraoperative miosis. Conclusion: FLACS has low complication rate with effective results. High cost of technology is still the main barrier against its popularity.

Background/Objectives: To evaluate the efficacy and safety of using the preservative-free topical proxymetacaine hydrochloride (Minims, 0.5% w/v, Bausch & Lomb, UK) to control postoperative pain after epithelium-off corneal crosslinking (CXL) for keratoconus. Methods: This is an observational study of patients with mild to severe keratoconus who have undergone epithelium-off CXL. CXL was completed by applying dextran-free riboflavin (0.1%) for 10 min (Vibex Rapid; Avedro, Inc.), followed by continuous UV-A light (Avedro KXL system; Avedro, Inc.) for 30 min at an intensity of 3 mW/cm² and an energy of 5.4 J/cm². All patients were prescribed postoperative proxymetacaine hydrochloride PRN with an allowed frequency of up to eight times per 24 h for the first 3 days to control postoperative pain. Patients were reviewed at 1–2 weeks postoperatively for a comprehensive examination, including assessment of delayed corneal healing, removal of the bandage contact lens, and recording of subjective symptoms. Results: There were 223 eyes of 180 patients with a mean age of 24.9 ± 8.6 years (range: 13–38 years). Male patients were 72%. At their planned first postoperative visit, we found no corneal healing abnormalities, such as persistent epithelial defects, epithelial irregularities, or early postoperative stromal haze, in any patient. All patients subjectively reported that proxymetacaine drops helped them to control postoperative pain, particularly in the first 48 h. Conclusions: None of the patients reported pain after 3 days of using proxymetacaine drops up to eight times a day for the first 3 days. It appears to be a safe and effective solution to control postoperative pain without any complications.